EZZ Life Science Holdings Ltd Cash Flow Conversion Efficiency
EZZ Life Science Holdings Ltd cash flow conversion efficiency. Based on the latest financial reports, EZZ Life Science Holdings Ltd (EZZ) has a cash flow conversion efficiency ratio of -0.198x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.50 Million ≈ $-3.89 Million USD) by net assets (AU$27.81 Million ≈ $19.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of EZZ Life Science Holdings Ltd (2018–2024)
Cash flow conversion efficiency of EZZ Life Science Holdings Ltd from 2018 to 2024. This chart illustrates how EZZ Life Science Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EZZ Life Science Holdings Ltd stock price for real-time trading data and today's change.
EZZ Life Science Holdings Ltd Cash Flow Conversion Ratio Explained
EZZ Life Science Holdings Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
EZZ Life Science Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EZZ Life Science Holdings Ltd ranked by their cash flow conversion efficiency. Also see EZZ Life Science Holdings Ltd (EZZ) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Nordic Healthbrands AB (publ)
ST:NNH
|
-0.107x |
|
Merchant House International Ltd
AU:MHI
|
-0.197x |
|
Alvo Minerals Ltd
AU:ALV
|
-2.176x |
|
Zantat Holdings Berhad
KLSE:0301
|
0.023x |
|
Rocket One Inc.
NASDAQ:RKTO
|
-0.733x |
|
Moatable Inc
NYSE:MTBLY
|
0.025x |
|
SACCHERIA F.LLI FRANCES.
F:YV1
|
N/A |
|
Art Nirman Limited
NSE:ARTNIRMAN
|
0.004x |
Annual Cash Flow Conversion Efficiency for EZZ Life Science Holdings Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of EZZ Life Science Holdings Ltd from 2018 to 2024. Review EZZ cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$28.09 Million ≈ $19.87 Million |
AU$4.35 Million ≈ $3.08 Million |
0.155x | -46.20% |
| 2023-12-31 | AU$21.32 Million ≈ $15.09 Million |
AU$6.14 Million ≈ $4.35 Million |
0.288x | +4.67% |
| 2022-12-31 | AU$14.58 Million ≈ $10.32 Million |
AU$4.01 Million ≈ $2.84 Million |
0.275x | +64.84% |
| 2021-12-31 | AU$11.39 Million ≈ $8.06 Million |
AU$1.90 Million ≈ $1.35 Million |
0.167x | +565.80% |
| 2020-12-31 | AU$10.11 Million ≈ $7.15 Million |
AU$253.53K ≈ $179.39K |
0.025x | -93.38% |
| 2019-12-31 | AU$7.85 Million ≈ $5.56 Million |
AU$2.97 Million ≈ $2.10 Million |
0.379x | -25.04% |
| 2018-12-31 | AU$823.91K ≈ $582.97K |
AU$416.33K ≈ $294.58K |
0.505x | -- |
About EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consum… Read more